IVERIC bio Inc

• Country

  United States of America

• Sector

  Health Care

• Industry group

  Pharmaceuticals, Biotechnology & Life Sciences

• Industry

  Biotechnology

• Sub-sector

  Health Care

• Capitalization (millions of $)

  5512.1

• Ticker

  ISEE.O

• ISIN

  US46583P1021

• IPO date

• Availability on Russian exchanges

  No

• Reporting for

  2023-05-10

• Date fact. publication of reports

  2023-03-31

IVERIC bio, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of treatment options for retinal diseases. The Company is developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases (IRDs). The Company's therapeutics portfolio consists of Zimura (avacincaptad pegol), a complement C5 inhibitor, and IC-500, a high-temperature requirement A serine peptidase 1 protein (HtrA1) inhibitor. The Company's gene therapy portfolio consists of two product candidates in pre-clinical development, IC-100 and IC-200. The Company is developing IC-100 for rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) and IC-200 for bestrophin-1 (BEST1) related IRDs.